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assigned point values based on impact on survival: rupture
(10 points), anticoagulation usage (4 points), renal failure
(1 point), and female gender (1 point). Patients with the
lowest risk of mortality were those with a score ranging
from e4 to 1 (1.4% risk of mortality), followed by those
with a range of 2 to 6 (13.3% mortality risk), 7 to 12
(33% mortality risk), and ﬁnally 13 to 16 (45.5%) risk of
death. A risk register was created with these data.
Conclusions: This study demonstrates that not all pa-
tients with AAA between 5 and 5.5 cm are candidates for
surgery. Higher-risk patients may beneﬁt from endovascu-
lar aneurysm repair (EVAR), and those patients with
smaller aneurysm sizes and few risk factors may beneﬁt
from observation. Women, patients with renal failure, and
anticoagulated patients all have a greater risk of in-hospital
mortality. Patients who undergo EVAR have signiﬁcantly
lower in-hospital mortality, especially those patients who
have a ruptured AAA.
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Objectives: Patients considered for endovascular treat-
ment of superﬁcial femoral artery (SFA) disease present
with a wide array of lesion complexity and treatment op-
tions. This study aims to examine the cost drivers of SFA
stent treatment and their impact on outcome.
Methods: We retrospectively collected clinical and
ﬁnancial data on patients undergoing SFA stenting to eval-
uate the relationship between direct procedural cost and 1-
year patency. Adjuncts to SFA stenting were deﬁned as
stent grafts, atherectomy, re-entry, and embolic protection
devices.
Results: We studied 95 patients who underwent SFA
stenting from January 2010 to February 2012. Patients
were a mean age of 71 years, 62% were male, 41% were
diabetic, 46% had critical limb ischemia (CLI), and 24%
had a TASC C or D lesion. Primary patency at 1 year
was better in patients with claudication than those with
CLI (91% vs 74%, P ¼ .06). Whereas the rate of adjunct
use was similar in patients with claudication and CLI
(12%), more adjuncts were used in patients with TASC
C and D lesions (22% C and D, 8% A and B, P ¼ .09).
Mean direct costs for SFA stenting without adjunct use
was $2838 (95% conﬁdence interval, $2586-$3089),
whereas adjunct use increased mean costs to $7318
(95% conﬁdence interval, $4817-$9820; P < .01). Multi-
variate regression showed that TASC C/D classiﬁcation
and adjunct use were associated with the highest tertile
of costs, OR 13.5 and 36.8 respectively (P < .01). There
was no association between cost and primary patency
(Fig).
Conclusions: Adjunct devices are often necessary to
achieve technical success for treatment of TASC C and DSFA lesions. Their use is associated with increased cost,
yet has limited impact on midterm patency.
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Objectives: To determine if the retrocarotid dissection
technique has advantages over the standard caudal-cranial
approach in regards of bleeding, surgical time, vascular or
nervous injury, and hospital stay in patients with carotid
body tumors (CBT).
Methods: A prospective cohort of patients who under-
went surgical treatment with retrocarotid dissection tech-
nique (RC) at our institution between July 2007 and
January 2013 was reviewed. This cohort was compared
with a historical group of patients treated with standard
approach (SA; caudal-cranial dissection) between 1995 and
2007. Intraoperative parameters and operative outcomes
were compared using the Fisher exact test for categoric vari-
ables, and Mann-Whitney U test for continuous variables. A
P < .05 was considered as statistically signiﬁcant.
Results: A total of 68 resections (41 SA, 27 RC) in 68
patients (62 female and 8 male; mean age, 54.3 years) were
performed. Comparative analysis identiﬁed mean blood
loss of 476 mL (standard deviation [SD] 378 mL) in the
RC group and 694.39 mL (SD, 682 mL) for the SA cohort
(P <. 31). The mean surgical time was 172 minutes (SD,
60 minutes) for the RC group and 260 minutes (SD,
97.7 minutes) for the SA group (P <. 001). The hospital
stay was signiﬁcantly shorter for the RC group with an
